Semaglutide-induced Erectile Dysfunction: A Case Report on Glucagon-like-peptide1 (GLP-1) Agonist Medication

Abstract

This case report examines the potential relationship between Semaglutide use and worsening erectile dysfunction (ED) in a 55-year-old male engineer with a history of diabetes, hypertension, and dyslipidemia. Despite initial improvements in metabolic health following treatment with Glucophage, Amlodipine, and Simvastatin, the patient continued to experience persistent ED. After switching to a regimen including Ozempic (Semaglutide), he reported a significant decline in libido and difficulties maintaining erections, suggesting that the medication may have exacerbated his erectile issues. Notably, his sexual desire improved after discontinuing Semaglutide. This case highlights the potential sexual side effects of GLP-1 receptor agonists and emphasizes the need for healthcare providers to monitor sexual health in patients undergoing treatment using GLP-1 agonists for metabolic syndrome (MetS). Future research should focus on larger studies to better understand the impact of Semaglutide on sexual health outcomes. Malaysian Journal of Medicine and Health Sciences (2026) 22(SUPP4):207-209.doi:10.47836/mjmhs.22.s4.37